Bridgebio Pharma Stock Price, News & Analysis

BridgeBio Pharma announced that the first patient has been dosed in a Phase 0/2 clinical trial of infigratinib, an investigational drug targeting FGFR genetic alterations in recurrent high-grade glioma patients. This trial aims to confirm the drug’s effectiveness in crossing the blood-brain barrier and hitting molecular targets. Patients showing positive pharmacokinetic responses will continue treatment post-surgery. The primary endpoint is a six-month progression-free survival rate. FGFR alterations are present in 5-7% of glioblastoma cases, highlighting the drug's potential impact.

BridgeBio Pharma's affiliate, QED Therapeutics, has initiated the PROPEL 2 Phase 2 clinical trial, dosing the first child with achondroplasia using infigratinib, an oral medicine targeting FGFR3. This trial aims to assess safety and measure height growth impact. Preclinical data show potential for significant growth improvement. CEO Michael Henderson emphasized the trial's significance, highlighting the extensive preparatory work. Infigratinib operates as a selective tyrosine kinase inhibitor, and the trial follows previous assessments demonstrating its efficacy at lower doses.

BridgeBio Pharma's affiliate, Phoenix Tissue Repair, announced the presentation of interim safety and tolerability data from a Phase 1/2 trial for PTR-01, a recombinant collagen 7 therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). The results will be shared virtually during the Society for Pediatric Dermatology’s Annual Meeting from July 10-12, 2020. PTR-01 has previously shown promising preclinical results, with Orphan Drug Designation granted by the FDA and EMA. Currently, no approved therapies exist for DEB, and the standard care is limited to wound management.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on July 1, 2020, that it granted stock options for 7,120 shares and restricted stock units for 15,134 shares to eight employees. The exercise price for the stock options is set at $30.34. These awards are part of BridgeBio's 2019 Inducement Equity Plan and were granted to incentivize employees joining the company, complying with Nasdaq Listing Rule 5635(c)(4). Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and has over 20 programs in its pipeline.

BridgeBio Pharma (NASDAQ: BBIO) announced the appointment of three new independent directors: Brent Saunders, Randy Scott, Ph.D., and Andrew Lo, Ph.D. Saunders, former CEO of Allergan, brings expertise in scaling businesses, having driven significant product launches and revenue growth. Scott, a leader in genomics, aims to revolutionize genetic medicine application, while Lo will leverage his financial engineering background to enhance funding strategies. This leadership expansion aims to accelerate the development of innovative therapies for genetic diseases.

BridgeBio Pharma (NASDAQ: BBIO) has announced a strategic collaboration with the University of Florida to advance research in genetically driven diseases into clinical development. This partnership aims to leverage the University’s expertise in gene therapy alongside BridgeBio's capabilities in therapeutics. The collaboration focuses on providing sponsorship for select research programs, including strategies for optimizing small-molecule therapies and conducting proof-of-concept studies. BridgeBio aims to establish long-term partnerships to facilitate the advancement of groundbreaking research into viable therapies.

BridgeBio Pharma (NASDAQ: BBIO) has announced a collaboration with Johns Hopkins University to advance the clinical development of therapies targeting genetically driven diseases. The partnership aims to apply academic innovations into viable treatments, focusing on gene therapy and small molecules. CEO Neil Kumar expressed excitement over leveraging Johns Hopkins' research for potential patient benefits. BridgeBio intends to establish long-term partnerships in biomedical research, reinforcing its commitment to addressing Mendelian diseases, with over 20 programs in its pipeline.

Phoenix Tissue Repair, an affiliate of BridgeBio Pharma (Nasdaq: BBIO), provided updates on its Phase 1/2 study of PTR-01 for recessive dystrophic epidermolysis bullosa (RDEB). The initial cohorts showed that PTR-01 was well tolerated across nine patients, with no serious adverse events reported. Furthermore, a dose-dependent increase in collagen 7 skin deposition was observed. The trial is progressing with a fourth cohort, and results may lead to a six-month open-label study. Dr. Sanuj K. Ravindran has been appointed as the executive chairman, focusing on creating a systemic treatment for RDEB.

BridgeBio Pharma (Nasdaq: BBIO) announced its Q1 2020 financial results, reporting a net loss of $91.9 million, up from $61.2 million in Q1 2019. The company holds $928.4 million in cash and equivalents, ensuring operational stability amid COVID-19 challenges. Clinical trials are ongoing but slowed in enrollment due to the pandemic. BridgeBio aims to file multiple NDAs and INDs later this year. Despite operational hurdles, recent financing raised $550 million, positioning them to progress their pipeline of 20+ drug programs through 2022.